ClexBio

Revolutionizing tissue regeneration for a healthier future

What is the Challenge?

Chronic diseases, such as liver failure, present significant challenges due to limited treatment options and the scarcity of donor organs. Traditional therapies often fail to provide long-term solutions, leading to prolonged patient suffering and increased healthcare burdens. For instance, liver transplants remain the primary treatment for end-stage liver disease, but donor shortages and high costs make this option inaccessible to many patients. There is a pressing need for innovative therapies that can effectively restore organ function and improve patient outcomes.

What is the Solution?

ClexBio is pioneering the development of bioengineered tissues that closely mimic human biology, offering new possibilities for regenerative medicine. Their proprietary platform combines multiple cell types to create complex tissue structures designed to restore organ function. Initially focusing on hepatocyte-based liver tissue products, ClexBio aims to provide viable alternatives to liver transplants, addressing the critical shortage of donor organs and offering hope to patients with end-stage liver disease.

Beyond liver applications, ClexBio’s technology holds promise for treating a wide range of chronic diseases. By developing scalable, off-the-shelf tissue therapies, they seek to transform the therapeutic landscape, making advanced treatments more accessible and affordable. Their innovative approach not only addresses current medical needs but also sets the stage for future advancements in tissue engineering and regenerative medicine.

ClexBio is a part of EQT Foundation’s Portfolio.

Latest